JBIO - Jade Biosciences, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$44.33
DETAILS
HIGH:
$55.00
LOW:
$34.00
MEDIAN:
$45.00
CONSENSUS:
$44.33
UPSIDE:
111.60%
About Jade Biosciences, Inc. (https://jadebiosciences.com)
Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specifically targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway, aiming to treat immunoglobulin A (IgA) nephropathy. Clinical trials for JADE-001 are slated to commence in the latter half of 2025, with initial results projected for the first half of 2026. Beyond this lead asset, the company's robust pipeline includes two preclinical antibody programs, JADE-002 and JADE-003.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Tom Frohlich | President, CEO & Director | 1976 | $1,019,883 USD |
| Andrew James King | President of Research & Development | 1980 | $765,901 USD |
| Bradford D. Dahms | CFO & Treasurer | 1989 | $350,051 USD |
| Amy Sullivan | Senior Vice President of Development Operations | – | – |
| Edward R. Conner | Chief Medical Officer | 1973 | – |
| Elizabeth Balta | Chief Legal Officer & Corporate Secretary | 1971 | – |
| Jason Wright | Senior Vice President of Chemistry, Manufacturing & Controls | – | – |
| Jonathan Quick | Senior Vice President of Finance | – | – |
| Lori Stewart | Senior Vice President of People | – | – |
| Sandy Lewis | Senior Vice President, Biometrics & Clinical Strategy | – | – |
| Valerie Fauvelle | Senior Vice President of Regulatory & Quality | – | – |